Trial Condition(s):

Retinal Vein Occlusion

Retrospective data analysis of patients treated for Macular Edema due to Central Retinal Vein Occlusion (RETRO CRVO)

Bayer Identifier:

18586

ClinicalTrials.gov Identifier:

NCT02645747

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The objective of this retrospective chart review is to evaluate drug utilization, usage patterns and indication of effectiveness Eylea in the routine clinical (real-life) management of patients who suffer from ME (Macular Edema), secondary to CRVO (Central Retinal Vein Occlusion), and who started treatment with Eylea for this indication.

Inclusion Criteria
- Male or female adult patients who suffer from visual impairment due to ME secondary to CRVO 
 - Anti-VEGF treatment-naive patients who started reimbursed Eylea treatment between the 1st of June 2014 and the 28th of February 2015
Exclusion Criteria
- Patients diagnosed with neovascular glaucoma secondary to CRVO will be excluded.

Trial Summary

Enrollment Goal
126
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Belgium

Status
Completed
 

Trial Design